News
Jeil Pharmaceutical secures rights to cefiderocol , a siderophore cephalosporin antibacterial drug, in South Korea
Shionogi said that its group company Ping An-Shionogi (Hong Kong) has concluded a sublicense agreement to grant South Korea’s Jeil Pharmaceutical the exclusive rights to develop and market the new siderophore cephalosporin antibacterial drug cefiderocol in the country
Ping An-Shionogi holds the exclusive development and commercialization rights to the drug in Asian countries excluding Japan, based on a license agreement with Shionogi.
Condition: Infectious Diseases/UTI
Type: drug